<p>Mangoceuticals, Inc. (MGRX) 发布了延迟提交的通知。</p>
<h3>季末特卖 - TipRanks 50% 折扣</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以做出更聪明、更精准的决策</li>
<li>发现表现优异的股票投资理念，并升级为市场领先者的投资组合，使用智能投资者精选</li>
</ul>
<p>Mangoceuticals, Inc. 已通知投资者，它将在提交截至 2025 年 12 月 31 日的财务年度的 10-K 表格（年度报告）时延迟，具体通过 12b-25 表格进行通知。延迟提交涉及其向美国证券监管机构提交的年度报告，原定于 2026 年 3 月 31 日到期。</p>
<p>公司将延迟归因于其外部审计师需要额外时间来完成对 10-K 表格（年度报告）的审查。管理层表示，正在与审计师积极合作，以完成必要的程序并最终确定年度报告。</p>
<p>根据延期规则，Mangoceuticals 预计将在原定截止日期后的 15 个日历日内提交 10-K 表格（年度报告）。这一时间表将使公司保持在允许的宽限期内，并限制因延迟本身而导致的合规风险升级。</p>
<p>Mangoceuticals 不预期在提交盈利报表后，其运营结果与前一个财年相比会有显著变化。投资者仍应将所有关于预期时间和未来结果的评论视为前瞻性声明，这可能会受到审计进展和其他不确定因素的影响。</p>
<p>公司强调其保持报告义务的意图，并确认在过去 12 个月内已提交所有其他所需的定期文件。该通知由首席执行官 Jacob D. Cohen 于 2026 年 3 月 31 日签署，强调了对延迟提交和补救工作的高层监督。</p>
<p><strong>关于 Mangoceuticals, Inc. 的更多信息</strong></p>
<p><strong>平均交易量：</strong> 12,820,032</p>
<p><strong>技术情绪信号：</strong> 卖出</p>
<p><strong>当前市值：</strong> 697 万美元</p>
<p>要深入了解 MGRX 股票，请访问 TipRanks 的概述页面。</p>

MGRX

标普生物技术 ETF - SPDR

纳斯达克生物科技指数 ETF - iShares Nasdaq

标普生物技术 3 倍做多 - Direxion

医药突破 ETF - ALPS

动态生物技术与基因组 ETF - Invesco

生物科技 ETF - VanEck Vectors

纽交所高增长板生物技术指数 ETF - First Trust

2 倍做多纳斯达克生物技术 ETF - ProShares

<p>Mangoceuticals, Inc. (MGRX) 宣布推迟提交截至 2025 年 12 月 31 日的 10-K 表格，原定于 2026 年 3 月 31 日到期。推迟的原因是外部审计师需要更多时间进行审查。公司预计将在原定截止日期后的 15 天内提交报告，并不预期财务结果会有重大变化。首席执行官 Jacob D. Cohen 签署了通知，强调管理层对合规和及时报告的承诺</p>

<p>Mangoceuticals, Inc. ( (MGRX) ) has released a notification of late filing.</p>
<div class="lb-trans"><p>Mangoceuticals, Inc. (MGRX) 发布了延迟提交的通知。</p>
</div><h3>End of Quarter Sale - 50% Off TipRanks</h3>
<div class="lb-trans"><h3>季末特卖 - TipRanks 50% 折扣</h3>
</div><ul>
<li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions</li>
<li>Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以做出更聪明、更精准的决策</li>
<li>发现表现优异的股票投资理念，并升级为市场领先者的投资组合，使用智能投资者精选</li>
</ul>
</div><p>Mangoceuticals, Inc. has notified investors that it will be late in filing its Form 10-K (Yearly Report) for the financial year ended December 31, 2025, via a Form 12b-25. The delayed filing concerns its annual report with the U.S. securities regulator, which was originally due on March 31, 2026.</p>
<div class="lb-trans"><p>Mangoceuticals, Inc. 已通知投资者，它将在提交截至 2025 年 12 月 31 日的财务年度的 10-K 表格（年度报告）时延迟，具体通过 12b-25 表格进行通知。延迟提交涉及其向美国证券监管机构提交的年度报告，原定于 2026 年 3 月 31 日到期。</p>
</div><p>The company attributes the delay mainly to its external auditor needing additional time to complete the review of the Form 10-K (Yearly Report). Management indicates it is working diligently with the auditor to finish the necessary procedures and finalize the annual report.</p>
<div class="lb-trans"><p>公司将延迟归因于其外部审计师需要额外时间来完成对 10-K 表格（年度报告）的审查。管理层表示，正在与审计师积极合作，以完成必要的程序并最终确定年度报告。</p>
</div><p>Under the extension rules, Mangoceuticals expects to file the Form 10-K (Yearly Report) no later than 15 calendar days after the original due date. That timetable would keep the company within the permitted grace period and limit the risk of any compliance escalation from the delay itself.</p>
<div class="lb-trans"><p>根据延期规则，Mangoceuticals 预计将在原定截止日期后的 15 个日历日内提交 10-K 表格（年度报告）。这一时间表将使公司保持在允许的宽限期内，并限制因延迟本身而导致的合规风险升级。</p>
</div><p>Mangoceuticals does not anticipate any significant change in its results of operations compared with the prior fiscal year once the earnings statements are filed. Investors should still treat all comments about expected timing and future results as forward-looking statements that may be affected by audit progress and other uncertainties.</p>
<div class="lb-trans"><p>Mangoceuticals 不预期在提交盈利报表后，其运营结果与前一个财年相比会有显著变化。投资者仍应将所有关于预期时间和未来结果的评论视为前瞻性声明，这可能会受到审计进展和其他不确定因素的影响。</p>
</div><p>The company emphasizes its intention to remain current with its reporting obligations and confirms that all other required periodic filings over the past 12 months have been submitted. The notification was signed on March 31, 2026, by Chief Executive Officer Jacob D. Cohen, underscoring executive-level oversight of the delayed filing and remediation efforts.</p>
<div class="lb-trans"><p>公司强调其保持报告义务的意图，并确认在过去 12 个月内已提交所有其他所需的定期文件。该通知由首席执行官 Jacob D. Cohen 于 2026 年 3 月 31 日签署，强调了对延迟提交和补救工作的高层监督。</p>
</div><p><strong>More about Mangoceuticals, Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Mangoceuticals, Inc. 的更多信息</strong></p>
</div><p><strong>Average Trading Volume:</strong> 12,820,032</p>
<div class="lb-trans"><p><strong>平均交易量：</strong> 12,820,032</p>
</div><p><strong>Technical Sentiment Signal:</strong> Sell</p>
<div class="lb-trans"><p><strong>技术情绪信号：</strong> 卖出</p>
</div><p><strong>Current Market Cap:</strong> $6.97M</p>
<div class="lb-trans"><p><strong>当前市值：</strong> 697 万美元</p>
</div><p>For an in-depth examination of MGRX stock, go to TipRanks’ Overview page.</p>
<div class="lb-trans"><p>要深入了解 MGRX 股票，请访问 TipRanks 的概述页面。</p>
</div>

Mangoceuticals Delays Annual 10-K Yearly Filing

Tip Ranks

Mangoceuticals

Mangoceuticals 推迟提交年度 10-K 报告